Letter to Editor
Published: 16 August, 2019 | Volume 2 - Issue 1 | Pages: 079-082
Allogeneic hematopoietic stem cell transplant (alloHSCT) is a curative treatment for many hematologic malignancies. Unfortunately, about 30-50% of all recipients undergoing alloHSCT develop acute graft-versus-host-disease (aGVHD), which is associated with high morbidity and mortality [1,2]. Treatment of aGVHD involves the use of immune suppressive drugs such as high dose of steroids that leads to further immunosuppression and risk for opportunistic infections. Often patients are refractory to steroids therapy making the prognosis dismal. Thus, it is critical to identify robust biomarkers to detect aGVHD before onset of clinical symptoms so that therapeutic strategies can be implemented that may result in better treatment responses and less toxicity.
Read Full Article HTML DOI: 10.29328/journal.ijbmr.1001007 Cite this Article Read Full Article PDF
Mir-155; Graft versus host disease, MicroRNA; Allogeneic stem cell transplant
Figure 1
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."